Announcements Trials

Browse Landscape

Phase

Status

Completed 71 Terminated 29 Withdrawn 4 Unknown 4 Active not recruiting 3 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1

Interventions

Drug Therapy 107 Cisplatin 98 Radiotherapy 89 Carboplatin 86 Bevacizumab 79 Oxaliplatin 74 Capecitabine 69 tislelizumab 68 Gemcitabine 64 Cyclophosphamide 64 toripalimab 62 Paclitaxel 58 pembrolizumab 56 Specimen Handling 54 sintilimab 53 Surgical Procedures, Operative 52 anlotinib 51 Magnetic Resonance Spectroscopy 50 Fluorouracil 49 Immune Checkpoint Inhibitors 43 Blood Specimen Collection 42 130-nm albumin-bound paclitaxel 42 Standard of Care 38 camrelizumab 36 fludarabine 35 Leucovorin 34 lenvatinib 33 venetoclax 30 Radiosurgery 30 Immunotherapy 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × Alemtuzumab × Clear all

NCT06084780 2026-06-05

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡